NCT04664023View on ClinicalTrials.gov

Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution

CompletedOBSERVATIONAL
Enrollment

130

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

June 19, 2023

Study Completion Date

June 19, 2023

Conditions
Covid19
Interventions
PROCEDURE

Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection.

40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis

PROCEDURE

Blood collection at 1st injection of vaccine against COVID-19, at at second injection of vaccine, at Month 1, Month 2, Month 6 and Month 12 after second injection of vaccine for volunteers

40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis

Trial Locations (1)

86000

C.H.U.de Poitiers, Poitiers

All Listed Sponsors
lead

Poitiers University Hospital

OTHER

NCT04664023 - Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution | Biotech Hunter | Biotech Hunter